The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in AML
In this video, Carmelo Gurnari, MD, Cleveland Clinic, Cleveland, OH, discusses the findings of a retrospective multicenter study conducted on behalf of the European Hematology Association (EHA) Acute Myeloid Leukemia (AML)-Specialized Working Group (SWG) that focused on the diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in AML. Dr Gurnari emphasizes that the potential benefit of FLT3 inhibitors in patients
with FLT3-ITD microclones should be evaluated in future randomized clinical trials. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
